As of Aug 28
| +0.09 / +0.51%|
The 7 analysts offering 12-month price forecasts for Aratana Therapeutics Inc have a median target of 28.00, with a high estimate of 38.00 and a low estimate of 23.00. The median estimate represents a +58.73% increase from the last price of 17.64.
The current consensus among 8 polled investment analysts is to Buy stock in Aratana Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.